Alnylam Q3 Revenue Reaches $1.46 Billion; Reaffirms 2026 Guidance
Q3 revenue exceeded FactSet consensus of $1.43 billion, with adjusted earnings of $16.26 per share. Product sales rose 59% year over year to $1.15 billion; the company cited slower US demand growth than in Q2. Revenue included a one-time $300 million Roche collaboration milestone payment. Alnylam reaffirmed full-year product revenue guidance of $4.7 billion to $5.1 billion.
Alnylam Pharmaceuticals reported Q3 2026 revenue of $1.46 billion, exceeding the FactSet consensus estimate of $1.43 billion, with adjusted earnings of $16.26 per share. The company's product sales for its hereditary transthyretin-mediated amyloidosis treatments, Amvuttra and Onpattro, rose 59% year-over-year to $1.15 billion, though the company noted a slowdown in US demand growth compared to the second quarter. Revenue was further bolstered by a $300 million one-time milestone payment from a collaboration with Roche. Alnylam reaffirmed its full-year 2026 financial guidance, expecting total net product revenue between $4.7 billion and $5.1 billion.